Clinical trials: Liver Failure, Chronic
End Stage Renal Disease on Hemodialysis (Diagnosis)
HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
This is an open-label, single arm study design to evaluate HEPLISAV-B® in adults with ESRD who are initiating or undergoing hemodialysis.
- Trial name
- NCT03934736
- Testing
- HEPLISAV-B®
- Where
- 20 sites in United States
- Volunteers
- 119 people
- Sponsor
- Dynavax Technologies Corporation
Urea Cycle Disorder, Crigler-Najjar Syndrome
HepaStem Long-Term Safety Registry
All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Biosciences
- Conditions
- Urea Cycle Disorder, Crigler-Najjar Syndrome, Acute on Chronic Liver Failure
- Trial name
- PROLONGSTEM (NCT03343756)
- Where
- 29 sites in Belgium, Bulgaria and 3 more
- Volunteers
- 44 people
- Sponsor
- Cellaion SA
Liver Failure, Acute on Chronic, Liver Injury
A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China
The definition and diagnostic criteria of Acute-on-chronic liver failure (ACLF) has been well established by EASL CANONIC study. However, patients with high risk to develop ACLF has not been determined, yet.
- Trial name
- NCT03281265
- Testing
- standard treatment
- Volunteers
- 1,178 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Liver Failure, Acute Liver Injury, Drug Induced
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
The clinical trial will assess the safety of miroliverELAP for the treatment of acute liver failure, severe acute alcohol-associated hepatitis, or acute on chronic liver failure.
- Conditions
- Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
- Trial name
- NCT06285253
- Testing
- miroliverELAP treatment
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Miromatrix Medical Inc.
Chronic Hepatitis B
Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment
The purpose of this study is to show that the combination of entecavir and tenofovir, is effective and well tolerated in chronic hepatitis B patients who have failed previous treatment.
- Trial name
- NCT01063036
- Testing
- Entecavir, Tenofovir
- Where
- 28 sites in France, Germany and 5 more
- Volunteers
- 144 people
- Sponsor
- Bristol-Myers Squibb
28 Day Mortality
Thromboelastography Guides a Multicentre Cluster Controlled Study of Plasma Exchange for Hepatitis B Associated Acute-on-chronic Liver Failure
In the past ten years, the extracorporeal liver support system has been widely used in clinical practice as a first-line treatment of liver failure.
- Trial name
- NCT04747106
- Testing
- plasma exchange
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute-On-Chronic Liver Failure
Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients
The goal of this clinical trial is to learn if CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection (hereinafter referred to as CG-BM1) can treat acute-on-chronic liver failure (ACLF) patients.
- Trial name
- NCT06740149
- Testing
- Bone marrow mesenchymal stem cells (low dose), Solvent of CG-BM1, Bone marrow mesenchymal stem cells (medium dose)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- GuangZhou Cellgenes Biotechnology Co., Ltd.
Acute on Chronic Liver Failure
Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Related Outcomes (GOAL Trial)
SIRS in ACLF exacerbate adverse effects of ammonia - sarcopenia, infections, immune dysfunction, HE and organ dysfunction Persistent or incident hyperammonemia during first week of hospitalization in patients with ACLF is…
- Trial name
- NCT06808009
- Testing
- Lactulose, Rifaximin, Standard Medical treatment
- Where
- India
- Volunteers
- 90 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Failure
Nomogram Analysis for HBV Related Acute-on-chronic Liver Failure
Acute-on-chronic liver failure (ACLF) is an acute deterioration of chronic liver diseases, which progresses rapidly, with a mortality rate of more than 50%.MELD score is used to evaluate the patients' condition.
- Trial name
- NCT03992898
- Testing
- No special intervention was suitable for this observational study
- Where
- China
- Volunteers
- 2,739 people
- Sponsor
- Sun Yat-sen University
Chronic Graft-Versus-Host Disease (cGVHD)
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD.
- Trial name
- NCT06619561
- Testing
- Vimseltinib
- Where
- 26 sites in United States
- Volunteers
- 48 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Coronary Artery Disease, Arterial Stiffness, Blood Pressure
Expanded Studies on the SCAPIS Stockholm Reexamination Cohort
The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a unique, large-scale national research initiative involving 30,000 randomly selected individuals aged 50-64, recruited between 2014 and 2018.
- Conditions
- Coronary Artery Disease, Arterial Stiffness, Blood Pressure, AORTIC VALVE DISEASES, Mitral Valve Stenosis and/or Insufficiency
- Trial name
- SCAPIS-ReEx (NCT07476703)
- Testing
- Coronary computer tomography (CCTA), Echocardiograhy and aortic ultrasound, Liver elastography
- Where
- Sweden
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Danderyd Hospital
Acute-On-Chronic Liver Failure
Platelet Transfusion in Acute-on Chronic Liver Failure
Acute on-chronic liver failure (ACLF) is a severe liver disease with a 28-day mortality rate of up to 40%. When the patients get 3 or more organ failures, the 28-day mortality rate is up to 82.6%.
- Trial name
- NCT04564651
- Testing
- platelet transfusion
- Where
- 8 sites in China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Decompensation of Liver Cirrhosis, Established Acute-on-Chronic Liver Failure
Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients with Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
- Trial name
- CONTROL-ACLF (NCT07694297)
- Testing
- NTZ 500mg BID on top of SOC
- Volunteers
- 16 people
- Sponsor
- Genfit
ESRD, Hepatitis C
Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR
It is well recognized that a subset of patients who contracts Hepatitis C virus (HCV) spontaneously clears the virus. Such individuals are anti-HCV antibody positive, yet HCV RNA PCR negative in the blood.
- Trial name
- NCT02669966
- Testing
- Kidney transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Florida
Chronic Liver Failure
Aerobic Capacity Muscle Strength and Health Related Quality of Life in Children With Chronic Liver Disease
Physical therapy program for children with chronic liver disease consist of gait training, strengthening ex for UL\&ll, stretching exercise to improve physical fitness and quality of life
- Trial name
- NCT06240832
- Testing
- Physical therapy exercise
- Where
- Egypt
- Volunteers
- 18 people
- Sponsor
- Cairo University
Hepatitis C Virus Infection, Response to Therapy of
Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4
Primary Efficacy Objective -To assess whether a 12-week treatment course with oral 50 mg elbasvir plus 100 mg grazoprevir given in a single daily dose to treatment-naïve patients with end-stage renal disease (ESRD) and infected…
- Trial name
- CLEAR-C4 (NCT03381859)
- Testing
- Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
- Where
- Egypt
- Sponsor
- University of Maryland, Baltimore
Acute on Chronic Hepatic Failure
Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure
50 patients of Acute-on-chronic liver failure (ACLF) will be enrolled and randomized into G-CSF+EPO or Placebo arms Treatment protocol To administer G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and…
- Trial name
- NCT01383460
- Testing
- Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)
- Where
- India
- Volunteers
- 55 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatitis B, ESRD (End Stage Renal Disease)
Comparing Hepatitis B Vaccination Schedules in Patients on Hemodialysis
People with kidney failure who are on dialysis have a weaker immune response to the hepatitis B vaccine than healthy people. Even after vaccination, many dialysis patients do not develop enough protection against hepatitis B…
- Conditions
- Hepatitis B, ESRD (End Stage Renal Disease), Kidney Failure, Chronic
- Trial name
- 3v4-HEP-DOSE (NCT07784452)
- Testing
- Recombinant Hepatitis B Vaccine - 3-Dose Schedule, Recombinant Hepatitis B Vaccine - 4-Dose Schedule
- Where
- Pakistan
- Volunteers
- 104 people
- Sponsor
- Jinnah Hospital
Metastatic Cancer, Congestive Heart Failure
Reducing Disparities in the Quality of Advance Care Planning for Older Adults
This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community.
- Conditions
- Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease
- Trial name
- EQUALACP (NCT03516994)
- Testing
- Respecting Choices First Steps, Five Wishes Form
- Where
- 4 sites in United States
- Volunteers
- 790 people
- Sponsor
- Duke University
Hepatic Encephalopathy, Cirrhosis, Liver
Integrated Traditional Chinese and Clinical Medicine for Chronic Hepatitis B and Its Complication
Hepatic encephalopathy is the most common complication after TIPS, and hepatic encephalopathy occurs in almost all portosystemic shunts.
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Liver, Portosystemic Shunt
- Trial name
- NCT05128305
- Testing
- traditional Chinese medicine1 and traditional Chinese medicine 2
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Qianfoshan Hospital